A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
Servicios
Servicios
Fecha de publicación
2015Título de revista
ANNALS OF ONCOLOGY
Tipo de contenido
Artigo
